According to a report by Bloomberg citing people familiar with the matter,Advent International (Advent International）And Blackstone Group (Blackstone) or consider acquisitionSanofiConsumer healthcare business, with the acquisition amount possibly reaching up to 20 billion US dollars.Other interested acquirers include Bain Capital, CVC Capital Partners, EQT AB, and KKR & Co.In December 2019, under the new Chief Executive Officer (CEO)Six months after Paul Hudson took office,Sanofi proposed the plan to spin off its consumer health business for the first time in order to concentrate resources on the development of original drugs and vaccines. After the plan was put forward, Sanofi made some minor moves, such as selling various consumer health products and spinning off India.Consumer Healthcare Business. However, the spin-off planUntil2023 yearsOctoberhas only just begun to become clear (see:Sanofi: Launch Strategic Cost Plan, Spin Off Consumer Health Business, Increase R&D Investment）。Consumer HealthcareAlthough this business is not Sanofi's main operation, it has contributed significantly to its revenue sources. In 2023, the revenue from this business grew to 5.18 billion euros (approximately 5.664 billion US dollars).
In the past 5 yearsSanofi Consumer Health Business Revenue (Unit: Billion Euros)In recent years, "decluttering" seems to be becoming the choice for large pharmaceutical companies to streamline their businesses. MNCs such as Pfizer, GSK, and Johnson & Johnson have divested their consumer health businesses to focus on the development and promotion of higher-value innovative drugs.
Copyright © 2024 PHARMCUBE. All Rights Reserved.
Welcome to forward, share, and reasonably cite. When citing, please clearly indicate the source of the article in a prominent position;For reprint, please leave a message or send a message to the WeChat Official Account backend, and indicate the name and ID of the official account.
Disclaimer: The information in this WeChat article is for general reference only and should not be directly used as decision-making content. PharmaCube assumes no responsibility for any loss incurred by any party due to the use of the content herein.
